Local biotech expands to the UK

Posted 27 November 20224 AM

Melbourne-based peanut allergy company Aravax, which has backing from the Novartis Venture Fund and Twiggy Forrest's Tenmile, has expanded into the UK, forming a subsidiary there as part of its manufacturing plans.

Aravax is currently running a Phase 2 trial of PVX108 to treat peanut allergies. It uses peptides recognised by T cells but without the allergens that trigger inflammation and acute reactions, which over time can drive a reduction in allergic sensitisation and reacquisition of tolerance.

To see the whole article, please login